

RECEIVED
CENTRAL FAX CENTER

AUG 04 2005

IN RE UNITED STATES PATENT APPLICATION No. 10/612,497TRANSMITTAL COVER LETTER FOR FACSIMILE TRANSMISSIONPLEASE DELIVER THE FOLLOWING PAGES TO: Mail Stop AFTELECOPIER NUMBER: 571.273.8300

THE SENDER IS:

Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000
Fax: (212) 596-9090

CLIENT NO. 000659.0030DOCKET NO. ABX-PF1 DIV1 USCERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

Isaiah B. SmithAugust 4, 2005

Date

TOTAL NUMBER OF PAGES, INCLUDING COVER LETTER: 3DATE: August 4, 2005

TIME: _____

TELECOPIER OPERATOR: Isaiah B. Smith

PLEASE ACKNOWLEDGE SAFE RECEIPT OF THIS TRANSMISSION BY
SIGNING AND RETURNING THIS COVER SHEET TO US BY FACSIMILE.
WE ACKNOWLEDGE SAFE RECEIPT OF THIS TRANSMISSION.

SIGNED: _____ DATE: _____

IF NOT, PLEASE CALL BACK AS SOON AS POSSIBLE. PHONE: (212) 596-9328

**RECEIVED
CENTRAL FAX CENTER**

AUG 04 2005

ABX-PF1 DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski
Group : 1644
Applicants : Douglas Charles Hanson et al.
Application No. : 10/612,497
Confirmation No. : 3552
Filed : July 1, 2003
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York
August 4, 2005

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF THE SUBSTANCE OF THE INTERVIEW

This is in response to a July 6, 2005 Interview Summary in the above-identified application. As required by the Interview Summary, applicants submit herewith a statement of the substance of a personal interview. Applicants are filing this statement before the expiration of the one month period from the mailing date of the Interview Summary and thus, this statement is timely filed.

At a June 16, 2005 personal interview, applicants' representatives, Jane Gunnison and Shilpa Patel, discussed the pending claims and prior art of record with Examiners Ouspenski and Gambel. The Examiners confirmed that some claims had already been found free of the prior art, including claims directed to anti-CTLA-4 antibodies comprising light chains that utilize

a human A27 Vk gene. Applicants indicated that some claims would be amended to include that language.

In a subsequent telephone call, the meaning of the term "utilizes a human A27 Vk gene" was discussed. Applicants' representative noted that as used in the claims and specification, this phrase encompasses light chains having amino acid sequences that comprise mutations as compared with the amino acid sequence encoded by the germline A27 Vk sequence. Applicants' representative also noted that the specification describes a number of such examples, including the light chain variable region amino acid sequence of antibody 4.1.1, now recited in claims 231-235. The Examiner indicated that he was in agreement as to that meaning in the claims and specification.

Respectfully submitted,

Jane T. Gummison
Jane T. Gummison (Reg. No. 38,479)
Attorney for Applicants

FISH & NEAVE IP GROUP
ROPES & GRAY LLP
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000
Fax: (212) 596-9090